Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor vs sulfonylurea for weight loss in obese patients with type 2 diabetes
ChiCTR2500104603Phase 4Not yet recruiting
- Sponsor
- Shantou Central Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shantou Central Hospital. Primary endpoints: Waist-to-height ratio, Body Mass Index and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2500104603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104603.